Protective effects of desacyl ghrelin on diabetic cardiomyopathy

详细信息    查看全文

• 作者：Xiao M. Pei ; Benjamin Y. Yung ; Shea P. Yip ; Lawrence W. Chan…
• 关键词：Fibrosis ; Autophagy ; Cardiomyopathy ; Type 2 diabetes mellitus ; Ghrelin
• 刊名：Acta Diabetologica
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：52
• 期：2
• 页码：293-306
• 全文大小：1,345 KB
• 参考文献：1. Voulgari, C, Papadogiannis, D, Tentolouris, N (2010) Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag 6: pp. 883-903 CrossRef
  2. Rubler, S, Dlugash, J, Yuceoglu, YZ, Kumral, T, Branwood, AW, Grishman, A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30: pp. 595-602 CrossRef
  3. Hosoda, H, Kojima, M, Matsuo, H, Kangawa, K (2000) Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 279: pp. 909-913 CrossRef
  4. Yang, J, Brown, MS, Liang, G, Grishin, NV, Goldstein, JL (2008) Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 132: pp. 387-396 CrossRef
  5. Gutierrez, JA, Solenberg, PJ, Perkins, DR (2008) Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci USA 105: pp. 6320-6325 CrossRef
  6. Lely, AJ, Tschop, M, Heiman, ML, Ghigo, E (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25: pp. 426-457 CrossRef
  7. Tesauro, M, Schinzari, F, Caramanti, M, Lauro, R, Cardillo, C (2010) Cardiovascular and metabolic effects of ghrelin. Curr Diabetes Rev 6: pp. 228-235 CrossRef
  8. Baldanzi, G, Filigheddu, N, Cutrupi, S (2002) Ghrelin and desacyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 159: pp. 1029-1037 CrossRef
  9. Nagaya, N, Uematsu, M, Kojima, M (2001) Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104: pp. 1430-1435 CrossRef
  10. Aoki, H, Nakata, M, Dezaki, K (2013) Ghrelin counteracts salt-induced hypertension via promoting diuresis and renal nitric oxide production in Dahl rats. Endocr J 60: pp. 571-581 CrossRef
  11. Frascarelli, S, Ghelardoni, S, Ronca-Testoni, S, Zucchi, R (2003) Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. Basic Res Cardiol 98: pp. 401-405 CrossRef
  12. Yang, C, Liu, Z, Liu, K, Yang, P (2014) Mechanisms of ghrelin anti-heart failure: inhibition of Ang II-induced cardiomyocyte apoptosis by down-regulating AT1R expression. PLoS ONE 9: pp. e85785 CrossRef
  13. Isgaard, J, Granata, R (2011) Ghrelin in cardiovascular disease and atherogenesis. Mol Cell Endocrinol 340: pp. 59-64 CrossRef
  14. Rodriguez, A, Gomez-Ambrosi, J, Catalan, V (2010) Association of plasma acylated ghrelin with blood pressure and left ventricular mass in patients with metabolic syndrome. J Hypertens 28: pp. 560-567 CrossRef
  15. Broglio, F, Arvat, E, Benso, A (2001) Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 86: pp. 5083-5086 CrossRef
  16. Barazzoni, R, Bosutti, A, Stebel, M (2005) Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle.
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Internal Medicine
  Diabetes
  Metabolic Diseases
  
• 出版者：Springer Milan
• ISSN：1432-5233

文摘

Aim Diabetic cardiomyopathy is a specific complication of type 2 diabetes mellitus, which causes progressive cardiac dysfunction. Desacyl ghrelin has been preliminarily demonstrated to have beneficial effects on cardiovascular system and glucose metabolism, which are both related to diabetic cardiomyopathy. The aim of this study was to investigate the protective effects of desacyl ghrelin on cardiac dysfunction, cardiac fibrosis, and cellular autophagy in a type 2 diabetic mouse model. Materials and methods Fourteen- to eighteen-week-old db/db diabetic and db/+ non-diabetic mice were intraperitoneally treated with desacyl ghrelin at a dosage of 100?μg/kg for ten consecutive days. Ventricular fractional shortening was examined as an indicator of cardiac function by transthoracic echocardiography. Results The presence of diabetic cardiomyopathy was evident by the reduction in fractional shortening shown in our examined db/db mice. Intriguingly, this reduction in fractional shortening was not observed in the hearts of db/db mice treated with desacyl ghrelin. Cardiac fibrosis (indicated by excessive collagen deposition, decreased by Adiponectin and Mmp13 expression, and up-regulated by Mmp8 expression) and impairment of autophagic signalling (indicated by decreases in Foxo3 and LC3 II-to-LC3 I ratio) were shown in the hearts of diabetic mice. All these cellular and molecular alterations were alleviated by desacyl ghrelin treatment. The key cardiac pro-survival cellular signals including AMPK, Akt, ERK1/2, and GSK3α/β were impaired in the diabetic hearts, but the administration of desacyl ghrelin attenuated these signalling impairments. Conclusions These results collectively demonstrate that desacyl ghrelin protects the heart against cardiac dysfunction in type 2 diabetic mice by inhibiting excessive collagen deposition and enhancing cardiac autophagic signalling via the pro-survival cellular AMPK/ERK1/2 signalling pathways.